Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Observational Study To Determine Velcade (Bortezomib) Safety and Effectiveness at First Relapse After Participation In First Line HOVON-49/50 Clinical Studies (ADVANCE)

Trial Profile

An Observational Study To Determine Velcade (Bortezomib) Safety and Effectiveness at First Relapse After Participation In First Line HOVON-49/50 Clinical Studies (ADVANCE)

Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Apr 2015

At a glance

  • Drugs Bortezomib (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms ADVANCE
  • Sponsors Janssen-Cilag
  • Most Recent Events

    • 15 Apr 2015 Status changed from discontinued to completed as reported by ClinicalTrials.gov record.
    • 04 Nov 2010 Planned End Date changed from 1 Apr 2011 to 1 Jul 2011 as reported by ClinicalTrials.gov.
    • 27 Apr 2010 Actual patient number (11) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top